The Senores Pharmaceuticals IPO Subscription Status on Day 2, with the issue subscribed 1.94 times by December 21, 2024. Retail Individual Investors (RIIs) led the charge, oversubscribing their portion by an impressive 7.90 times, while Non-Institutional Investors (NIIs) subscribed 1.77 times. Although Qualified Institutional Buyers (QIBs) showed limited participation at 0.01 times, their involvement is expected to rise in the final days of the offering. This enthusiastic response highlights the strong market confidence in Senores Pharmaceuticals’ growth potential and industry leadership.
Senores Pharmaceuticals IPO Subscription Status
| Investor Category | Subscription (Times) |
|---|---|
| Retail Individual Investors (RIIs) | 7.90 |
| Non-Institutional Investors (NIIs) | 1.77 |
| Qualified Institutional Buyers (QIBs) | 0.01 |
| Overall | 1.94 |
Retail Individual Investors (RIIs) have driven demand, oversubscribing their category nearly 8 times. Non-institutional investors followed with a subscription of 1.77 times, while Qualified Institutional Buyers (QIBs) are expected to step in during the final days of the offering.
Senores Pharmaceuticals IPO Grey Market Premium Today
The GMP is a crucial indicator of market sentiment for an IPO before its listing. For Senores Pharmaceuticals, the premium of ₹185 reflects positive investor sentiment and high demand. While a strong GMP is encouraging, remember that it is subject to fluctuations and should be considered alongside the company’s fundamentals.
Key IPO Details
| Detail | Information |
|---|---|
| Price Band | ₹372 to ₹391 per share |
| Lot Size | 38 shares |
| Minimum Investment | ₹14,858 |
| Issue Size | ₹582.11 crore |
| IPO Dates | December 20 to December 24, 2024 |
| Expected Allotment Date | December 26, 2024 |
| Expected Listing Date | December 30, 2024 |
The IPO consists of a fresh issue of ₹200 crore and an Offer for Sale (OFS) of ₹382.11 crore from existing shareholders, bringing the total issue size to ₹582.11 crore.
About Senores Pharmaceuticals
Senores Pharmaceuticals is a prominent player in the pharmaceutical industry, specializing in the development, manufacturing, and marketing of generic drugs. The company serves a variety of therapeutic areas, including cardiology, dermatology, and gastroenterology, and has a strong presence in both domestic and global markets.
What’s Next?
With two days left for subscription, investor interest is expected to pick up further, especially from QIBs. The final share allotment is set for December 26, 2024, with the company’s stock expected to debut on the exchanges on December 30, 2024.
The strong response so far underscores Senores Pharmaceuticals’ robust reputation and promising future in the pharmaceutical sector, making this IPO one of the year’s most anticipated offerings.
Pravin Bhosale
I am finance blogger with a Bachelor’s degree in Electrical Engineering. Since stepping into the world of trading in 2019, i have gained valuable experience navigating the markets, have knowldge in indices like Bank Nifty, Nifty IT, Sensex, Bankex, and Finifty. our blog aims to make finance approachable, offering practical insights for readers to better understand and act on market trends.